FiercePharma | Nachrichten

Zeit	Aktuelle Nachrichten
Sa	ESMO: Roche's Tecentriq posts 'unprecedented' benefit in triple-negative breast cancer
Sa	ESMO: Pfizer's narrow Ibrance survival miss could still sway docs in its favor: exec
Fr	AbbVie CFO Chase spearheaded its Abbott spinoff and Imbruvica buy-and now he's retiring
Fr	NICE spurns Lilly's breast cancer drug Verzenio in favor of rivals from Pfizer and Novartis
Fr	Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout
Fr	After Philippines safety scandal, Sanofi's Dengvaxia set for European approval
Fr	FiercePharmaAsia-China's $1.3B vaccine fine; Lantus biosim retreat; Taiho's VC fund
Fr	ESMO 2018 spotlights Merck's Keytruda, Pfizer's Ibrance, AstraZeneca's Lynparza and more
Fr	Clovis bolsters Rubraca's PARP-leading prostate cancer bid with big-time response data
Do	Novartis' canakinumab gets an FDA rejection, but it raises guidance anyway
Do	Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win
Do	Insys drove 'explosive' opioid painkiller sales by 'owning' physicians, Senate report reveals
Do	AbbVie wards off another Humira biosim challenger with Fresenius Kabi settlement
Do	GlaxoSmithKline's job whacking touches U.S. consumer plant
Do	Working through CEO swap, Pfizer plots job cuts in drive for 'simpler' structure
Mi	Even in worst-case scenario, Roche will grow past biosimilar erosion in the U.S.: executive
Mi	Mannkind's Afrezza Facebook page gets slapped by FDA's promo police
Mi	U.K. fights EpiPen shortage by extending injector expiry dates
Mi	Minnesota AG targets Sanofi, Eli Lilly and Novo Nordisk in latest insulin pricing attack
Mi	Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?
Mi	Amgen, Lilly migraine drugs nab Express Scripts backing, but Teva's shut out
Mi	Merck joins Novartis, GSK in grabbing a consumer exec to beef up digital
Mi	FDA spanks South Korea's Hanlim Pharm with warning letter
Mi	Officials deny shortage of Seqirus' Fluad in the U.K. as season nears
Mi	News of Note-Sanofi's Dengvaxia, HPV vaccine and more

Zeit

Aktuelle Nachrichten

ESMO: Roche's Tecentriq posts 'unprecedented' benefit in triple-negative breast cancer

ESMO: Pfizer's narrow Ibrance survival miss could still sway docs in its favor: exec

AbbVie CFO Chase spearheaded its Abbott spinoff and Imbruvica buy-and now he's retiring

NICE spurns Lilly's breast cancer drug Verzenio in favor of rivals from Pfizer and Novartis

Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout

After Philippines safety scandal, Sanofi's Dengvaxia set for European approval

FiercePharmaAsia-China's $1.3B vaccine fine; Lantus biosim retreat; Taiho's VC fund

ESMO 2018 spotlights Merck's Keytruda, Pfizer's Ibrance, AstraZeneca's Lynparza and more

Clovis bolsters Rubraca's PARP-leading prostate cancer bid with big-time response data

Novartis' canakinumab gets an FDA rejection, but it raises guidance anyway

Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win

Insys drove 'explosive' opioid painkiller sales by 'owning' physicians, Senate report reveals

AbbVie wards off another Humira biosim challenger with Fresenius Kabi settlement

GlaxoSmithKline's job whacking touches U.S. consumer plant

Working through CEO swap, Pfizer plots job cuts in drive for 'simpler' structure

Even in worst-case scenario, Roche will grow past biosimilar erosion in the U.S.: executive

Mannkind's Afrezza Facebook page gets slapped by FDA's promo police

U.K. fights EpiPen shortage by extending injector expiry dates

Minnesota AG targets Sanofi, Eli Lilly and Novo Nordisk in latest insulin pricing attack

Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?

Amgen, Lilly migraine drugs nab Express Scripts backing, but Teva's shut out

Merck joins Novartis, GSK in grabbing a consumer exec to beef up digital

FDA spanks South Korea's Hanlim Pharm with warning letter

Officials deny shortage of Seqirus' Fluad in the U.K. as season nears

News of Note-Sanofi's Dengvaxia, HPV vaccine and more

Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von

Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Xetra-Orderbuch

Devisen	Kurs	%

Rohstoffe	Kurs	%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)

Aktuelle News von FiercePharma